PDE Assay Services
Phosphodiesterase (PDE) screening is performed with an activity assay format based on the hydrolysis of cyclic AMP and cyclic GMP. Inhibition of PDEs prevents the regulation of these second messengers and was found useful in the treatment of a variety of conditions including pulmonary hypertension, acute refractory cardiac failure, erectile dysfunction, etc.
- The activity of PDEs is measured with the Transcreener AMP2/GMP2 FP PDE assay platform (BellBrook labs)
- Low and large scale screening, as well as high-throughput PDE screening options, are available
- Custom-tailored PDE assay development possible
At Reaction Biology, we offer PDE screening services for pharma, biotech, and academic institutions with a commitment to quality data and quality service. Our global business development team is available to discuss your PDE assay needs with you today.
List of PDE Assays (16 total)
| Target | Synonyms | UniProt | Data |
|---|---|---|---|
| PDE10A | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Q9Y233 | Data sheet |
| PDE1A | Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | P54750 | Data sheet |
| PDE1B | Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Q01064 | Data sheet |
| PDE1C | Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Q14123 | Data sheet |
| PDE2A | cGMP-dependent 3',5'-cyclic phosphodiesterase | O00408 | Data sheet |
| PDE3A | cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Q14432 | Data sheet |
| PDE3B | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Q13370 | Data sheet |
| PDE4A | cAMP-specific 3',5'-cyclic phosphodiesterase 4A | P27815 | Data sheet |
| PDE4B | cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Q07343 | Data sheet |
| PDE4C | cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Q08493 | Data sheet |
| PDE4D | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Q08499 | Data sheet |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | O76074 | Data sheet |
| PDE7A | High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Q13946 | Data sheet |
| PDE8A | High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | O60658 | Data sheet |
| PDE9A | High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A | O76083 | Data sheet |
| PDE7B | cAMP-specific 3',5'-cyclic phosphodiesterase 7B | Q9NP56 | Data sheet |
PDE Screening Details
PDE converts cAMP or cGMP to AMP or GMP which displace a fluorescent tracer from an antibody selective for AMP and GMP resulting in a reduction of the fluorescence polarization signal.
Setups: Single-dose screening in duplicates or IC50 value determination with 5 or 10 concentrations. Other screening formats are available upon request.
Controls: No inhibitor (DMSO vehicle) control and for every assay, one target-specific control compound is tested in 10-dose IC50 format.
Turnaround time: 10 business days for standard projects. Expedited scheduling and data delivery can be arranged prior to the commencement of the studies.
Report: The raw data, % enzyme activity and control compound IC50 values will be reported in Excel format for single-dose assays. For IC50 orders, raw data, IC50 values, and curve fitting will be delivered in Excel format. Assay conditions, target, and substrate information are available upon request. Requirements for this information should be noted prior to the commencement of the study.
Screening facility: This assay is performed at our screening facility in Malvern, PA, US.
Compound requirements: In brief, for a standard project, 20 µl of a 10 mM DMSO stock or solid material is needed. Less material is needed for large scale screening. Please refer to our FAQs for information regarding compound preparation and shipping.
On a monthly basis, Reaction Biology performs compound screening on the full phosphodiesterase panel.
Please see the upcoming screening dates here.
Related Services
